Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By Sue Sutter
Drug Review Profile: Vafseo
The FDA approved Akebia's Vafseo for treatment of anemia in chronic kidney disease patients on dialysis. • Source: Shutterstock

More from Drug Review Profiles

More from Product Reviews